|
Jul 29
|
5 Stocks With Recent Price Strength to Maximize Your Gains
|
|
Jul 28
|
Here is Why Growth Investors Should Buy Orion OYJ (ORINY) Now
|
|
Jul 28
|
Orion OYJ (ORINY) is on the Move, Here's Why the Trend Could be Sustainable
|
|
Jul 21
|
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
|
|
Jun 23
|
141,959 Orion Corporation A shares converted into B shares
|
|
Jun 20
|
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
|
|
Jun 17
|
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
|
|
May 22
|
Orion to host Capital Markets Day today, 22 May 2025, in Helsinki
|
|
May 21
|
Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers
|
|
Mar 11
|
Orion Group Financial Statement documents 2024 and Remuneration Report published
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Julia Macharey
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Hao Pan
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – René Lindell
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Olli Huotari
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Liisa Hurme
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Niclas Lindstedt
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Outi Vaarala
|
|
Mar 11
|
Orion Corporation: Managers’ transactions – Satu Ahomäki
|
|
Mar 10
|
Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025
|